// App-Quantinova.ai

4561 : Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).

Researchers

Presenter

  • Amishi Yogesh Shah

Principal Investigators

  • Robert J. Motzer

  • Andrea B. Apolo

  • Thomas Powles

  • Bernard Escudier

  • Joshua Zhang

  • Christian Scheffold

  • Sravan Karumanchi

  • Linh Thuy Nguyen

  • Toni K. Choueiri

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust,, London, United Kingdom

  • Gustave Roussy, Villejuif, France

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Exelixis, Alameda, CA

  • Ann Arbor Pharmacometrics Group, Ann Arbor, MI

  • Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, MA

Locations

  • United States

  • United Kingdom

  • France

Companies

  • Exelixis, Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Dermatology

  • Oncology (ONC)

  • Cardiovascular (CVS)

Disease

  • Hand foot syndrome

  • Metastatic Renal Cell Cancer

  • Renal cell carcinoma

  • Hypertension

  • Solid malignancies

Biomarkers

  • Aspartate aminotransferase

  • Alanine transaminase

Drug/Treatment

  • Cabozantinib

  • Nivolumab

  • Sunitinib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • III

Study Id's

  • NCT03141177

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved